Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Cell Dev. Biol.

Sec. Cancer Cell Biology

Volume 13 - 2025 | doi: 10.3389/fcell.2025.1672461

Corrigendum: PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway

Provisionally accepted
Huafu LiHuafu Li1Chunming WangChunming Wang1LINXIANG LANLINXIANG LAN2Wenhui WuWenhui Wu1Ian EvansIan Evans2E Josue RuizE Josue Ruiz2Leping YanLeping Yan1Zhijun ZhouZhijun Zhou3Joaquim Miguel OliveiraJoaquim Miguel Oliveira4Rui L. ReisRui L. Reis4Hu ZhenranHu Zhenran1Wei ChenWei Chen1Axel BehrensAxel Behrens2Yu-Long HeYu-Long He1Changhua ZhangChanghua Zhang1*
  • 1Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
  • 2The Francis Crick Institute, London, United Kingdom
  • 3The University of Oklahoma, Norman, United States
  • 43B's Research Group, Barco, Portugal

This article is a correction to:

  1. PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway

    1. Read original article

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Dear Editor, We are so sorry that we need to make a Corrigendum of our paper of ”PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway”. We have put the wrong image of Figure 2 G and Figure 4 A by mistake. But doesn’t influence the data. Here the image which is correct and could you please help us to do the Corrigendum? FIGURE 2 | PARP1 is upregulated in oxaliplatin resistance gastric cancer. (G) Representative images of PARP1 levels stained by immunofluorescence in organoid and tumors. The scale bar represents 20 µm for tumour images, 200 µm for organoid images. FIGURE 4 | PARP1 inhibition by Olaparib sensitizes gastric cancer to Oxaliplatin. (A–C) rGC1 organoids were treated with Olaparib + Oxaliplatin, Oxaliplatin, and Olaparib, respectively, before imaging (A), number of organoids (B), and size of organoids (C). The scale represents 500 µm. Best regards, Changhua Zhang

Keywords: Corrigendum, PARP1 inhibitor, Figure 2 G, Figure 4 A, oxaliplatin

Received: 24 Jul 2025; Accepted: 08 Aug 2025.

Copyright: © 2025 Li, Wang, LAN, Wu, Evans, Ruiz, Yan, Zhou, Oliveira, Reis, Zhenran, Chen, Behrens, He and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Changhua Zhang, Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material